collection
MENU ▼
Read by QxMD icon Read
search

Drug Advertising

shared collection
10 papers 0 to 25 followers
By Carlos Adanero Pharmacist
https://www.readbyqxmd.com/read/22913661/ethical-considerations-in-studying-drug-safety-the-institute-of-medicine-report
#1
Michelle M Mello, Steven N Goodman, Ruth R Faden
The tumult arising from revelations of serious safety risks associated with widely prescribed drugs, including rosiglitazone (Avandia, GlaxoSmithKline), rofecoxib (Vioxx, Merck), and celecoxib (Celebrex, Pfizer), has led to widespread recognition that improvement is needed in our national system of..
September 6, 2012: New England Journal of Medicine
https://www.readbyqxmd.com/read/23822654/toward-patient-centered-drug-development-in-oncology
#2
Ethan Basch
As an oncologist, when I sit with patients to discuss starting a new chemotherapy regimen, their first questions are often "How will it make me feel?" and "How did patients like me feel with this treatment?" Regrettably, this information is generally missing from U.S. drug labels and from published..
August 1, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/23942130/the-drug-facts-box-improving-the-communication-of-prescription-drug-information
#3
Lisa M Schwartz, Steven Woloshin
Communication about prescription drugs ought to be a paragon of public science communication. Unfortunately, it is not. Consumers see $4 billion of direct-to-consumer advertising annually, which typically fails to present data about how well drugs work. The professional label--the Food and Drug Administration's (FDA) mechanism to get physicians information needed for appropriate prescribing--may also fail to present benefit data. FDA labeling guidance, in fact, suggests that industry omit benefit data for new drugs in an existing class and for drugs approved on the basis of unfamiliar outcomes (such as depression rating scales)...
August 20, 2013: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/21812664/restrictions-on-the-use-of-prescribing-data-for-drug-promotion
#4
Michelle M Mello, Noah A Messing
Pharmaceutical manufacturers spend billions of dollars each year sending sales representatives, known as detailers, into physicians' offices. To promote their drugs, detailers show up at medical offices bearing product information and valuable drug samples. They also wield a third critical tool:..
September 29, 2011: New England Journal of Medicine
https://www.readbyqxmd.com/read/16076787/benefits-and-harms-of-direct-to-consumer-advertising-a-systematic-review
#5
REVIEW
S Gilbody, P Wilson, I Watt
BACKGROUND: Direct to consumer advertising is increasingly used by the pharmaceutical industry, but its benefits and harms have yet to be summarised in a comprehensive and rigorous manner. METHODS: A systematic review was conducted of robust evaluations of the impact (positive and negative) of direct to consumer advertising. A broad range of databases and data sources (including Cinahl, Embase, HMIC, HSRProj, Medline, PsycInfo, and the internet) were searched from inception to 2004...
August 2005: Quality & Safety in Health Care
https://www.readbyqxmd.com/read/17401016/direct-to-consumer-advertising-in-oncology-a-content-analysis-of-print-media
#6
Gregory A Abel, Stephanie J Lee, Jane C Weeks
PURPOSE: Content analysis of cancer-related direct-to-consumer advertising (DTCA), with a focus on how benefit and risk/adverse effect information is presented, is essential to understanding its potential impact on oncology outcomes. METHODS: We reviewed all oncology DTCA appearing in three patient-focused cancer magazines and a sample of selected popular magazines from January 2003 to June 2006. We determined the Flesch reading ease score (FRES) for the text in each advertisement (a score > or = 65 is readable for the average person)...
April 1, 2007: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/15855433/influence-of-patients-requests-for-direct-to-consumer-advertised-antidepressants-a-randomized-controlled-trial
#7
RANDOMIZED CONTROLLED TRIAL
Richard L Kravitz, Ronald M Epstein, Mitchell D Feldman, Carol E Franz, Rahman Azari, Michael S Wilkes, Ladson Hinton, Peter Franks
CONTEXT: Direct-to-consumer (DTC) advertising of prescription drugs in the United States is both ubiquitous and controversial. Critics charge that it leads to overprescribing, while proponents counter that it helps avert underuse of effective treatments, especially for conditions that are poorly recognized or stigmatized. OBJECTIVE: To ascertain the effects of patients' DTC-related requests on physicians' initial treatment decisions in patients with depressive symptoms...
April 27, 2005: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/17699817/a-decade-of-direct-to-consumer-advertising-of-prescription-drugs
#8
Julie M Donohue, Marisa Cevasco, Meredith B Rosenthal
BACKGROUND: Evidence suggests that direct-to-consumer advertising of prescription drugs increases pharmaceutical sales and both helps to avert underuse of medicines and leads to potential overuse. Concern about such advertising has increased recently owing to the withdrawal from the market of heavily advertised drugs found to carry serious risks. Moreover, the Food and Drug Administration (FDA) has been criticized for its weak enforcement of laws regulating such advertising. METHODS: We examined industry-wide trends in spending by pharmaceutical companies on direct-to-consumer advertising and promotion to physicians during the past decade...
August 16, 2007: New England Journal of Medicine
https://www.readbyqxmd.com/read/23469165/promotion-of-prescription-drugs-to-consumers-and-providers-2001-2010
#9
Rachel Kornfield, Julie Donohue, Ernst R Berndt, G Caleb Alexander
BACKGROUND: Pharmaceutical firms heavily promote their products and may have changed marketing strategies in response to reductions in new product approvals, restrictions on some forms of promotion, and the expanding role of biologic therapies. METHODS: We used descriptive analyses of annual cross-sectional data from 2001 through 2010 to examine direct-to-consumer advertising (DTCA) (Kantar Media) and provider-targeted promotion (IMS Health and SDI), including: (1) inflation-adjusted total promotion spending ($ and percent of sales); (2) distribution by channel (consumer v...
2013: PloS One
https://www.readbyqxmd.com/read/24679064/ethical-pharmaceutical-promotion-and-communications-worldwide-codes-and-regulations
#10
REVIEW
Jeffrey Francer, Jose Zamarriego Izquierdo, Tamara Music, Kirti Narsai, Chrisoula Nikidis, Heather Simmonds, Paul Woods
The international pharmaceutical industry has made significant efforts towards ensuring compliant and ethical communication and interaction with physicians and patients. This article presents the current status of the worldwide governance of communication practices by pharmaceutical companies, concentrating on prescription-only medicines. It analyzes legislative, regulatory, and code-based compliance control mechanisms and highlights significant developments, including the 2006 and 2012 revisions of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code of Practice...
2014: Philosophy, Ethics, and Humanities in Medicine: PEHM
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"